newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

LEXINGTON, Mass., March 29, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ te